Examqo › Examqo library › Geriatric medicine › Conditions in older adults · IMLE
Diabetes in older adults: individual targets and deintensification
In an older adult the HbA1c target is set by health, function and cognition — below 7.0%–7.5% in a healthy older adult, below 8.0% in one with many diseases or mild functional decline, and in poor health a numerical target is dropped and the aim is mainly to avoid hypoglycaemia and symptoms of high glucose.
Why it matters in the exam
The exam presents an older adult with dementia and falls who takes insulin or glibenclamide and has an HbA1c of 6.3%, and asks what to do: deintensify treatment, because hypoglycaemia is far more dangerous for him than slightly high glucose. Candidates are also asked which drugs are preferred: metformin (when clearance is above 30), DPP-4 inhibitors for their low risk of hypoglycaemia, and SGLT2 inhibitors or GLP-1 RA for kidney and heart benefit — with caution about dehydration and weight loss.
Recurring points: sulfonylureas (especially glibenclamide) and "sliding-scale" insulin alone in institutions — avoid; hypoglycaemia in older adults sometimes presents as confusion, a fall or neurological signs rather than sweating and palpitations; and diabetes is linked to cognitive decline, depression, urinary incontinence and falls — so screen for them.
The exam also asks about a patient in an institution or at the end of life: simplify treatment, drop a strict diet, measure glucose less often, and take care only to avoid very low glucose and very high glucose that causes thirst, frequent urination and dehydration. Candidates are also asked about routine checks that still matter — feet, eyes, kidneys and blood pressure — and about the link between diabetes and cognitive decline: a patient who cannot manage insulin alone needs a simple regimen and help.
Key points
- Individual target: healthy — below 7.0%–7.5%; complex — below 8.0%; poor health — no numerical target.
- Hypoglycaemia is more dangerous than slightly high glucose.
- Reduce insulin and sulfonylureas when glucose is below target.
- Avoid glibenclamide and "sliding-scale" insulin alone.
- Screen for cognitive decline, depression, falls and urinary incontinence.
Summary table
| Patient's state | HbA1c target | Fasting glucose |
|---|---|---|
| Healthy — few diseases, intact cognition and function | Below 7.0%–7.5% | 80–130 mg/dL |
| Complex — many diseases, mild-to-moderate cognitive or functional decline | Below 8.0% | 90–150 mg/dL |
| Poor health — terminal illness, moderate-to-severe dementia, dependence | No numerical target; avoid hypoglycaemia and symptoms | 100–180 mg/dL |
| Drugs to avoid | Glibenclamide, "sliding-scale" insulin alone | Beers 2023 |
| Preferred drugs | Metformin, DPP-4 inhibitor, SGLT2 inhibitor, GLP-1 RA, cautious basal insulin | Match to clearance and weight |
In the full version for subscribers
- A simple algorithm
- Memory aid
- Exam traps
- 5 review cards
- Enough for IMLE
The full version is open to subscribers of: Geriatrics, Medical licensing exam (IMLE), Internal medicine, Family medicine.
Subscriber? Read the full topic Plans and prices 25 free questions
Sources
- American Diabetes Association — Standards of Care in Diabetes, Older adults, 2025 — Glycaemic targets, hypoglycaemia and deintensification
- Endocrine Society clinical practice guideline — Treatment of diabetes in older adults, 2019 — Individualised targets
- American Geriatrics Society Beers Criteria, 2023 update — Sulfonylureas and sliding-scale insulin
Sources are given for further reading; the text is written afresh and not copied from them.
Reviewed by the Examqo AI Professor · 2026-11-06. The text may contain errors; when in doubt, check the source.